Checkpoint CD24 function on tumor and immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• CD24 is a cell surface protein crucial for cancer cell proliferation, invasion, and metastasis.
• CD24 interacts with Siglec-10 on immune cells, inhibiting natural killer cell and macrophage functions.
• This interaction allows tumor cells to evade immune surveillance and destruction.

Purpose of the Study:

• To review the role of CD24 in the immune system and cancer progression.
• To evaluate CD24 as a potential immune checkpoint target for cancer immunotherapy.
• To summarize current and emerging therapeutic strategies targeting CD24.

Main Methods:

• Literature review of preclinical and clinical studies on CD24.
• Analysis of CD24's interaction with Siglec-10 and its impact on anti-tumor immunity.
• Examination of therapeutic approaches including monoclonal antibodies, CAR T cells, and gene therapy.

Main Results:

• CD24-Siglec-10 interaction suppresses anti-tumor immune responses.
• Monoclonal antibodies targeting CD24 are well-tolerated and safe in clinical trials.
• Preclinical studies demonstrate the potential of CAR T cells, antibody-drug conjugates, and gene therapy.

Conclusions:

• CD24 is a significant mediator of immune evasion in cancer.
• CD24 represents a promising immune checkpoint target for novel cancer immunotherapies.
• Further research and clinical development of CD24-targeted therapies are warranted.